公司表示，熊慧、熊钧目前未在公司担任董事或高级管理人员职务，上述事项不会对公司日常经营活动产生重大不利影响。公司具备完善的法人治理结构 与内部控制体系，各项经营管理工作均有明确的流程保障，公司日常经营管理由高管团队负责，董事及高级管理人员目前均正常履职。目前，公司业务正 常开展，经营活动正常进行。 据悉，熊慧毕业于复旦大学微生物学专业，曾成功开发国内首个应用于临床的基于一代测序平台的HBV耐药突变检测试剂盒。熊慧与熊钧系姐弟关系。 2024年7月，公司收到通知，董事长、总经理熊慧，实际控制人、时任董事兼时任副总经理熊钧及时任副总经理薛愉玮因涉嫌非法经营被公安机关采取指 定居所监视居住措施，时任副总经理何俊彦涉嫌非法经营被公安机关采取刑事拘留措施。 2024年10月，公司收到上述人员家属通知，熊慧、熊钧、薛愉玮、何俊彦的强制措施变更为刑事拘留，涉嫌罪名变更为诈骗罪。2024年12月，熊慧、熊钧 因涉嫌诈骗罪已被批捕，案件已经进入检察机关审查起诉阶段。 1月23日，睿昂基因还发布业绩预告，预计2025年年度实现营业收入为1.7亿元至1.76亿元。公司预计2025年年度实现归母净利润约亏损3991万元至5986万 ...

Core Viewpoint - The company, Shanghai Ruian Gene Technology Co., Ltd., anticipates a significant decline in its financial performance for the year 2025, projecting a revenue drop and net losses compared to the previous year [3][5]. Financial Performance Forecast - The company expects to achieve an operating revenue between 170 million to 176 million yuan for the year 2025 [3]. - The projected net loss attributable to the parent company is estimated to be between -39.91 million to -59.86 million yuan [3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -49.91 million to -69.86 million yuan [3]. Previous Year Performance - In 2024, the company reported an operating revenue of 242.31 million yuan and a net loss of -15.76 million yuan [5]. - The earnings per share for 2024 were -0.28 yuan per share [6]. Reasons for Performance Changes - The decline in revenue is attributed to intensified competition in the in vitro diagnostics industry and specific adverse events affecting the company, leading to a revenue decrease of approximately 66.31 million to 72.31 million yuan, representing a year-on-year decline of 27.36% to 29.84% [7]. - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for bad debts [7]. - The company has halted its molecular diagnostic reagent R&D center and industrialization project, recognizing impairment losses due to the lack of a continuation plan [7]. - Impairment losses have also been recognized for subsidiaries due to deteriorating market conditions, affecting their goodwill and major assets [7]. - The overall performance decline of both the parent and subsidiary companies has led to a reassessment of deferred tax assets due to limited future taxable income [7]. Other Information - The financial data provided is preliminary and has not been audited by registered accountants [4][8]. - The company has not identified any significant uncertainties that would affect the accuracy of the performance forecast as of the announcement date [8].

Core Viewpoint - Ruiang Gene's actual controllers, Xiong Hui and Xiong Jun, are facing legal action for fraud, which has been officially filed by the prosecution [2][4]. Group 1: Legal Issues - Ruiang Gene announced that its actual controllers, Xiong Hui and Xiong Jun, have been sued for fraud by the prosecution [2]. - Both individuals were previously detained and are now facing formal charges [4]. - The company stated that Xiong Hui and Xiong Jun do not hold any current positions as directors or senior management, and this situation is not expected to significantly impact the company's daily operations [4]. Group 2: Company Management Changes - Gao Shangxian has taken over as chairman and general manager, succeeding Xiong Hui, who is his spouse [4]. - The actual controllers of Ruiang Gene include Xiong Hui, Gao Shangxian, Xiong Jun, and Gao Ze, collectively holding 30.62% of the company's shares [5][6]. Group 3: Financial Performance - Ruiang Gene reported a net loss of 15.76 million yuan in 2024, a decrease of 298.78% compared to the previous year [6][7]. - The company anticipates a further net loss for 2025, estimated between 39.91 million yuan and 59.86 million yuan [6]. - The decline in revenue is attributed to intensified competition in the in vitro diagnostics industry, slower customer payments, and the suspension of certain projects [7].

Shareholder Reductions - Guohang's shareholder Guofeng Investment Innovation Fund plans to reduce its stake by no more than 1.02% [1] - Wenzhou Hongfeng's actual controller Chen Xiao intends to reduce his stake by no more than 3% [1] - Zhongqi New Materials' shareholder Zhou Jun and his concerted parties plan to reduce their stake by no more than 3% [1] - Anji Food's actual controller and chairman Lin Xiaofang plans to reduce his stake by no more than 3% [1] - Hanbo High-tech plans to reduce no more than 2% of its repurchased shares [1] - Runyang Technology's director Tong Xiaoling plans to reduce his stake by no more than 0.8% [1] - Kelin Electric's shareholder Zhang Chengsuo plans to reduce a total of 3.7956 million shares [1] - Andeli's shareholder Guangzhou Tongyi has cumulatively reduced 3.3418 million shares [1] - Fangda Special Steel's director Xu Zhixin plans to reduce no more than 730,900 shares [1] - Wangbian Electric's shareholder Yang Houqun has reduced 2.1896 million shares [1] - Huibo Yuntong and Yitongda plan to reduce no more than 0.59% of their shares [1] Other Significant Events - *ST Changya's stock is suspended and may face delisting [1] - Ruiang Gene's actual controllers Xiong Hui and Xiong Jun have been prosecuted for fraud [1]

Mergers and Acquisitions - Weixing New Materials plans to acquire 88.2557% equity of Beijing Songtiancheng Technology Co., Ltd. for 111 million yuan, focusing on the development, manufacturing, and sales of polyethylene valves for municipal pipeline networks [1] - Yunnan City Investment intends to publicly transfer 10.5% equity of Kunming Qicai Yunnan Urban Construction Investment Co., Ltd. with a base price of 293 million yuan [2] Shareholding Changes - Pengling Co., Ltd.'s actual controller Wang Zhifang plans to increase his shareholding by 20 million to 40 million yuan within six months, reflecting confidence in the company's business transformation and long-term investment value [3] - Anji Food's controlling shareholder Lin Xiaofang intends to reduce his stake by up to 3%, amounting to a maximum of 705,600 shares, due to personal funding needs [4] - Zhongqi New Materials' shareholder Zhou Jun and his concerted action party plan to reduce their holdings by up to 3% of the company's shares [5] Earnings Forecasts - Guocheng Mining forecasts a net profit attributable to shareholders of 1 billion to 1.12 billion yuan for 2025, compared to a profit of 453 million yuan in the same period last year [6] - Palm Shares anticipates a net loss of 1 billion to 1.2 billion yuan for 2025 [7] - Daoshi Technology expects a net profit attributable to shareholders of 480 million to 580 million yuan for 2025, representing a year-on-year growth of 206.01% to 269.76% [8] Risk Matters - Zhongbai Group received a warning letter from the Hubei Securities Regulatory Bureau due to untrue financial data disclosures and failure to timely disclose litigation and arbitration amounts exceeding 10% of the latest audited net assets [9] - Ruiang Gene's actual controllers Xiong Hui and Xiong Jun have been prosecuted for fraud, following their earlier arrest [10]

熊慧女士、熊钧先生目前未在公司担任董事或高级管理人员职务，上述事项不会对公司日常经营活动产 生重大不利影响。 睿昂基因(688217.SH)发布公告，前期，公司实际控制人熊慧女士、熊钧先生因涉嫌诈骗罪已被批捕。 近日，公司收到实际控制人熊慧女士、熊钧先生家属的通知，实际控制人熊慧女士、熊钧先生因涉嫌诈 骗罪已被检察机关向法院提起诉讼。 ...

Core Viewpoint - The actual controllers of Ruian Gene, Ms. Xiong Hui and Mr. Xiong Jun, have been arrested for fraud and are now facing litigation initiated by the prosecution [1] Company Impact - Ms. Xiong Hui and Mr. Xiong Jun are no longer serving as directors or senior management personnel in the company [1] - The ongoing legal issues are not expected to have a significant adverse impact on the company's daily operations [1]

Core Viewpoint - Ruiang Gene forecasts an annual revenue of 170 million to 176 million yuan for 2025, indicating a significant decline in profit due to various factors [1] Group 1: Revenue and Profit Decline - The company expects a revenue decrease of approximately 66.31 million to 72.31 million yuan in 2025, representing a year-on-year decline of 27.36% to 29.84% [1] - The decline in revenue has led to a reduction in gross profit [1] Group 2: Factors Contributing to Decline - Increased competition in the in vitro diagnostics industry and specific events affecting the company have negatively impacted revenue [1] - Slower payment collection from downstream clients due to the medical industry environment has resulted in increased provisions for credit impairment losses on accounts receivable [1] - The suspension of the molecular diagnostic reagent R&D center and industrialization project, with no plans for resumption, has led to impairment losses being recognized [1] - Performance declines in subsidiaries Shanghai Yuanqi Bio and Wuhan Baitai have prompted the company to recognize goodwill impairment losses and asset impairment losses, respectively, due to changes in the external market environment [1] Group 3: Tax Asset Adjustments - The significant decline in performance for both the parent and subsidiary companies has led to a reassessment of future taxable income, resulting in the write-off of previously recognized deferred tax assets [1]

Core Viewpoint - The actual controllers of Ruian Gene, Ms. Xiong Hui and Mr. Xiong Jun, have been arrested for fraud and are facing legal proceedings, but this situation is not expected to significantly impact the company's daily operations [1] Company Operations - The actual controllers, Ms. Xiong Hui and Mr. Xiong Jun, are no longer serving as directors or senior management, ensuring that the company’s daily operations remain unaffected [1] - The company has a robust corporate governance structure and internal control system in place, with clear processes to ensure operational management [1] - The executive team is currently managing the company's operations normally, and all directors and senior management are fulfilling their duties as expected [1] - Business activities are continuing as normal, indicating stability in the company's operational performance [1]

人民财讯1月23日电，睿昂基因(688217)1月23日公告，前期，公司实际控制人熊慧、熊钧因涉嫌诈骗罪 已被批捕。近日，公司收到实际控制人熊慧、熊钧家属的通知，实际控制人熊慧、熊钧因涉嫌诈骗罪已 被检察机关向法院提起诉讼。目前，公司业务正常开展，经营活动正常进行。睿昂基因同日公告，预计 2025年度实现归属于母公司所有者的净利润为亏损3990.69万元到5986.03万元。 ...